Can-Fite BioPharma (ADR) (CANF)
Develops oral A3AR-targeted drug candidates for psoriasis, liver cancer and metabolic liver disease.
$2.40
Pre-market+0.03 (+1.27%)
At close$2.37(−27.96%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions14 holders · as of Dec 31, 2025 | 45.56% | 29.8K ADS | |
| Otherremainder | 54.44% | 35.6K ADS |
65.5K ADS (1 ADS = 2 ordinary shares) as of Sep 3, 2026 · institutions as of Dec 31, 2025 · holders as of their latest filing
Two share counts disagree (65.5K in the company's Sep 3, 2026 report, 1.31M elsewhere); stakes use the report.
Institutions13F, as of Dec 31, 2025
14 holders · 596.5K shares · 3 new positions · 6 increased · 2 reduced · 4 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Rhumbline Advisers | 281.9K | 430.62% | +223.9K | Feb 13, 2026 |
| Jane Street Group, LLC | 205.0K | 313.17% | +205.0Knew | Feb 12, 2026 |
| Advisor Group Holdings, Inc. | 36.0K | 55.00% | +36.0K | Feb 17, 2026 |
| UBS Group AG | 20.9K | 31.99% | +19.6K | Jan 29, 2026 |
| XTX Topco Ltd | 18.7K | 28.55% | +18.7Knew | Feb 17, 2026 |
| Bogart Wealth, LLC | 15.0K | 22.98% | 0 | Jan 30, 2026 |
| Two Sigma Securities, LLC | 12.1K | 18.47% | +1.4K | Feb 17, 2026 |
| Fifth Third Bancorp | 3.0K | 4.58% | 0 | Feb 2, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.
